Table 2.
Comparisons of plasma biomarker levels (pg/mL) among normal controls and first-ever ischemic stroke patients with favorable and unfavorable outcomes
| Total (n = 259) | Favorable outcome (MRS 0–2) (n = 232) | Unfavorable outcome (MRS 3–6) (n = 27) | Normal group (n = 30) | P-value | |
|---|---|---|---|---|---|
| NT-pro-BNP | 397.0 (92.4–1027.0) | 306.5 (82.9–780.0) | 2359.5 (2022.4–3379.0) | 227.6 (125.7–440.1) | < 0.001 |
| LMP2 | 641.8 (368.4–860.3) | 614.0 (319.5–798.7) | 1131.9 (714.4–1473.0) | 221.5 (163.8–290.4) | < 0.001 |
| LMP5 | 410.1 (316.3–585.6) | 397.4 (306.8–553.9) | 684.9 (372.2–896.9) | 246.1 (182.5–283.6) | 0.002 |
| LMP7 | 293.0 (211.9–425.9) | 279.1 (203.6–383.0) | 652.8 (360.2–780.2) | 208.2 (155.1–256.9) | < 0.001 |
Data are expressed as medians with interquartile ranges and analyzed using the Kruskal–Wallis H test. LMP: Low molecular mass peptide; MRS: Modified Rankin Scale; NT-pro-BNP: N-terminal pro-B-type natriuretic peptide.